Evidence map›Paper›PMID 40684253›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome.

Indira Garcia-Cordero, Juan Camilo Vargas-Gonzalez, Mohsen Hadian, Ece Bayram, Federico Rodriguez-Porcel, Blas Couto, Jay Iyer, Lawrence I Golbe, Christopher D Stephen, Alexander Pantelyat and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  2. Article
  3. Article
  4. Article
  5. Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Indira Garcia-CorderoTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
Juan Camilo Vargas-GonzalezTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
Mohsen HadianTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
Ece BayramMovement Disorders Center, Department of Neurology, University of Colorado Anschutz, Aurora, Colorado, USA.
Federico Rodriguez-PorcelDepartment of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA.
Blas CoutoInstitute of Cognitive and Translational Neuroscience (INCyT-INECO-CONICET), Favaloro University Hospital, Buenos Aires, Argentina.
Jay IyerDepartments of Molecular and Cellular Biology and Statistics, Harvard University, Cambridge, Massachusetts, USA.
Lawrence I GolbeRutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Christopher D StephenDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Alexander PantelyatDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Marian L DaleDepartment of Neurology, Oregon Health & Science University, Portland, Oregon, USA.
Nikolaus McFarlandDepartment of Neurology, Norman Fixel Institute for Neurological Diseases, College of Medicine, University of Florida, Gainesville, Florida, USA.
Tao XieDepartment of Neurology, University of Chicago Medicine, Chicago, Illinois, USA.
Matthew SwanDepartment of Neurology, Mount Sinai Beth Israel, and Icahn School of Medicine, New York, New York, USA.
Kyurim KangMusic and Health Science Research Collaboratory (MaHRC), Faculty of Music, University of Toronto, Toronto, ON, Canada.
Douglas GunzlerPopulation Health and Equity Research Institute, Center for Health Care Research and Policy, MetroHealth Medical Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Anne-Marie WillsDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Adam BoxerDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, California, USA.
Irene LitvanDepartment of Neurosciences, University of California San Diego, San Diego, California, USA.
Anthony LangThe Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto, ON, Canada.
Maria Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.

Funding

The Progressive Supranuclear Palsy Clinical Trial Platform (PTP)R01AG085029 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L., LITVAN, IRENE · 2024 to 2025
$30.3M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Karen J. Bandeen-Roche · 2020 to 2026
$29.3M
Dementia with Lewy Bodies Consortium - Supplement for ASL sequenceU01NS100610 · NINDS · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI DOUGLAS R GALASKO, JAMES Bruce LEVERENZ · 2016 to 2026
$15.6M
Phase IIB: A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration SyndromesR44AG080861 · NIA · BIOSENSICS, LLC · PI ADAM L. BOXER, Irene Litvan · 2022 to 2026
$3.5M
Training in Research to Assure Neuroscience Scholars Cultivate Expertise in Notable Disparities Science (TRANSCENDS)R25NS098999 · NINDS · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI BRUCE OVBIAGELE · 2017 to 2026
$2.5M
Clinical Trial Readiness In X-Linked Dystonia Parkinsonism: Assessment of Sensor-Based And Blood Biomarkers for Early Detection and Monitoring Disease ProgressionK23NS118045 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI STEPHEN, CHRISTOPHER D · 2021 to 2025
$1.1M
Cerebellar TMS for postural instability in progressive supranuclear palsyK23NS121402 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Marian Livingston Dale · 2022 to 2026
$921k
Genetic and Neuropathologic Underpinnings of Sex Differences in Lewy Body DementiasR00AG073453 · NIA · UNIVERSITY OF COLORADO DENVER · PI ECE BAYRAM · 2024 to 2026
$725k
Defining the role of the subthalamic nucleus in language production through deep brain stimulationR21DC019749 · NIDCD · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RODRIGUEZ-PORCEL, FEDERICO · 2022 to 2023
$415k
Genetic and Neuropathologic Underpinnings of Sex Differences in Lewy Body DementiasK99AG073453 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BAYRAM, ECE · 2022 to 2023
$251k
AbbVieAlterityAlzheimer's Association Clinician Scientist FellowshipAmerican Academy of NeurologyAmerican Brain FoundationBIA R&DBiogen and BiohavenBiogen Inc.Cambridge University PressCurePSPEIP-PharmaGenentechHolloway Family Fund of The Association for Frontotemporal DegenerationInternational Parkinson and Movement Disorders SocietyLewy Body Dementia AssociationLundbeckMarion and Gerald Soloway Chair in Brain Injury and Concussion ResearchMedRhythms, IncMichael J Fox FoundationNIA/NIH 1R21NS114764-01A1NIA/NIH 5U01NS112010/807745NIA/NIH R01AG085029NIA/NIH R25NS098999NIA/NIH R44AG080861NIA/NIH U01NS100610NIA/NIH U19 AG063911-1NIA NIH HHS K99AG073453NIA NIH HHS P30 AG066507NIA NIH HHS R00 AG073453NIH HHS 1R21NS114764-01A1NIH HHS 2 P30 AG062429-06NIH HHS 5U01NS112010/807745NIH HHS K23 NS118045NIH HHS R21DC019749NIH HHS R25NS098999NIH HHS U01NS100610NIH HHS U19 AG063911-1NINDS NIH HHS K23 NS121402NovartisOno Pharmaceuticals, Accordant and CVS/CaremarkParkinson's FoundationRocheRutgers University PressSage TherapeuticsSanofi-Genzyme, SwanBio therapeutics and Encora TherapeuticsUCBVivli, Inc
6 · The paper itself

Abstract

introductionCognitive impairment is common but often overlooked due to motor symptoms in progressive supranuclear palsy-Richardson syndrome (PSP-RS). This study investigates whether cognitive deficits predict disease progression in PSP-RS.

methodsA total of 146 PSP-RS from the Tilavonemab trial were evaluated at baseline and over 52 weeks using the PSP-Rating Scale (PSPRS), the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and the Unified Parkinson's Disease Rating Scale Part-II (UPDRS-II). Multiple linear regression analyses were performed between the RBANS, UPDRS-II, and the PSPRS change. Clinical scores, gray matter volumes, and neurofilament-light chain (NfL) were compared using analyses of covariance (ANCOVAs) and linear mixed models between language score-groups.

resultsLower RBANS-language at baseline predicted greater PSPRS worsening over time. The low language-score group showed poorer cognitive performance, elevated NfL, and reduced gray matter volume in language-related areas. DISCUSSION: Speech/language deficits predict worse prognosis in PSP-RS, emphasizing the value of including language scores in clinical trials. HIGHLIGHTS: Speech and language deficits predict a worse prognosis in progressive supranuclear palsy-Richardson syndrome (PSP-RS). Lower language scores are associated with worse cognitive performance over time. Lower language scores related to higher neurofilament-light chain (NfL) at baseline. The low language-score group presented greater atrophy in language-related brain areas. Stratifying PSP-RS cases using language scores may improve clinical trials.

Indexed as

Language DisordersSupranuclear Palsy, ProgressiveAgedBrainDisease ProgressionFemaleGray MatterHumansMagnetic Resonance ImagingMaleMiddle AgedNeurofilament ProteinsNeuropsychological Testsneurofilament protein LNeurofilament Proteinscognitiondisease progressiongray matter volumelanguageneurofilament‐light chainPSP‐Rating ScalePSP‐Richardson syndromeRBANS

Identifiers

PMID40684253
PMCPMC12276069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.